Clinical Trial Update: Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 gene therapy trial for X-linked chronic granulomatous disease sponsored by Genethon has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Chronic Granulomatous Disease

Snippet

Sponsor: Genethon | Conditions: X-Linked Chronic Granulomatous Disease | Phase 1, Phase 2 | Status: TERMINATED